The 65 rating InvestorsObserver gives to Jazz Pharmaceuticals PLC (JAZZ) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 84 percent of stocks in the Biotechnology industry, JAZZs 65 overall rating means the stock scores better than 65 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 65 would rank higher than 65 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Jazz Pharmaceuticals PLC (JAZZ) stock is trading at $146.00 as of 2:22 PM on Monday, Nov 2, an increase of $1.90, or 1.32% from the previous closing price of $144.10. The stock has traded between $144.46 and $147.60 so far today. Volume today is low. So far 318,164 shares have traded compared to average volume of 537,338 shares.

Click Here to get the full Stock Score Report on Jazz Pharmaceuticals PLC (JAZZ) Stock.

More:
Is Jazz Pharmaceuticals PLC (JAZZ) a Winner in the Biotechnology Industry? - InvestorsObserver